Industry Analysts Just Upgraded Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Forecasts By 15% [Yahoo! Finance News]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance News
Esperion Therapeutics, Inc.NASDAQ:ESPRAfter this upgrade, Esperion Therapeutics' ten analysts are now forecasting revenues of US$199m in 2020. This would be a huge 34% improvement in sales compared to the last 12 months. Per-share losses are expected to explode, reaching US$7.27 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$174m and losses of US$7.33 per share in 2020. So there's been quite a change-up of views after the recent consensus updates, withthe analysts noticeably increasing their revenue forecasts while also expecting losses per share to hold steady.See our latest analysis for Esperion TherapeuticsGM:ESPR Past and Future Earnings April 21st 2020The consensus price target held steady at US$80.85 despite the upgrade to revenue forecasts and ongoing losses. Analysts seem to think the business is otherwise performing roughly in line with expectations. There's another way to think about price targets though, and that's to look at t
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ESPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With DiabetesGlobeNewswire
ESPR
Earnings
- 11/6/25 - Miss
ESPR
Sec Filings
- 1/12/26 - Form 8-K
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- ESPR's page on the SEC website